• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23488 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin/metformin - Addendum to Commission A16-13]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin/linagliptin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin: benefit assessment according to §35a Social Code Book V]
2020     National Committee for Technology Incorporation (CONITEC) [Empagliflozin and dapagliflozin for the treatment of type 2 diabetes mellitus]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (type 2 diabetes mellitus in children and adolescents) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (renal insufficiency) - Benefit assessment according to § 35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (heart failure) - Addendum to Commission A21-93]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (heart failure and preserved ejection fraction) - Addendum to Commission A22-39]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin - Addendum to Commission A16-12]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Emotional freedom technique]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emicizumab (haemophilia A) - Addendum to Commission A18-20]
2013     The Swedish Council on Health Technology Assessment (SBU) [Emergency care for the elderly patients who are in the poorest health]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Embolization or sclerotherapy of pelvic veins in pelvic congestion syndrome]
2002     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Embolization of uterine fibroids - Early Warning on New Health Technology]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Embolization in the treatment of uterine myoma]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide: addendum to commission A15-61]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (HIV-infected children) - Benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir/cobicistat/emtricitabine/ tenofovir disoproxil (HIV-1 in adolescents) - Benefit assessment according to §35a Social Code Book (SGB) V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (HIV infection, 2 to < 6 years) - Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elranatamab (multiples Myelom) - Addendum zum Projekt A24-12]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elranatamab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elotuzumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elotuzumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elotuzumab (multiple myeloma) - Addendum to Commission A19-80]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elotuzumab (multiple myeloma) - Addendum to Commission A16-32]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elotuzumab - Benefit assessment according to §35a Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elosulfase alfa (mucopolysaccharidosis type IVA) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (new scientific findings)]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elosulfase alfa - Assessment according to § 35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eliglustat - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Elexacaftor/tezacaftor/ivacaftor in cystic fibrosis]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Elexacaftor/tezacaftor/ivacaftor in cystic fibrosis]
2014     Haute Autorite de sante (HAS) [Elements to evaluate for managing a patient in outpatient surgery]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Electrosurgical units in surgery]
2007     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Electronic patient record at an osteoporotic outpatient department - a Health Technology Assessment]
2008     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Electronic patient record at an osteoporotic outpatient department - a health technology assessment]
2011     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Electronic Clinical Guides: breast cancer]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Electromagnetic Navigation Bronchoscopy: Use in Dying for Lung Nodules Resection. Horizon Scanning Technologies]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Electrical stimulation devices to treat delayed unions and pseudarthrosis]
2012     Haute Autorite de sante (HAS) [Elbow joint implants]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elbasvir/grazoprevir (chronic hepatitis C): Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elbasvir/grazoprevir (chronic hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eladocagene Exuparvovec (aromatic L-amino acid decarboxylase deficiency, = 18 months) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elacestrant (breast cancer) – Addendum to Project A23-104]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elacestrant (breast cancer; = 1 prior therapy) – Benefit assessment according to §35a Social Code Book V]
2009     Committee for New Health Technology Assessment (CNHTA) [ELA2 gene point mutation analysis]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eftrenonacog alfa (haemophilia B) – Benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eftrenonacog alfa - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Efmoroctocog alfa - Benefit assessment according to § 35a Social Code Book V]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [eFlow® vibrating membrane nebulizer for the treatment of cystic fibrosis]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Efgartigimod alfa (myasthenia gravis) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Efgartigimod alfa (generalized myasthenia gravis) – Benefit assessment according to §35a Social Code Book V]
2015     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Efficiency, effectiveness and safety of mechanical ventricular assistance with HeartWare® device in terminal heart failure]
2015     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Efficiency, effectiveness and safety of mechanical ventricular assistance with HeartWare® device in terminal heart failure]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Efficiency of the induction of personalised psychiatric rehabilitation through assessment of, and continuous feedback on, needs and outcomes - a catchment area observational trial]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Efficiency of the "housing first" approach for people who are homeless and living with mental illness or with disorders associated to psychoactive substances]
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Efficiency of short-term social and psychological therapies: Systematic review]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Efficiency of physiotherapeutic care in Parkinson's disease]
2013     Andalusian Health Technology Assessment Area (AETSA) [Efficiency of peritoneal dialysis versus hemodialysis for the treatment of renal insufficiency]
2020     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Efficiency of 3D reconstruction in maxillofacial surgery]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Efficiency in the use of operating surgical blocks. Definition of indicators]
2018     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Efficacy, safety, and usefulness of genistein in patients with Sanfilippo syndrome]
2008     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Efficacy, safety of high intensity focused ultrasound (HIFU-ExAblate)]
2004     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Efficacy, safety and indications of hybrid PET-CT system]
2013     Andalusian Health Technology Assessment Area (AETSA) [Efficacy, safety and efficiency of transcutaneous nerve stimulation for the treatment of chronic musculoskeletal pain]
2014     Andalusian Health Technology Assessment Area (AETSA) [Efficacy, safety and efficiency of platelet rich plasma in the treatment of aseptic nonunion]
2013     Andalusian Health Technology Assessment Area (AETSA) [Efficacy, safety and efficiency of electrical spinal cord stimulation for the treatment of chronic musculoskeletal pain]
2013     Andalusian Health Technology Assessment Area (AETSA) [Efficacy, safety and efficiency of computed tomographic colonography vs. colonoscopy as colorectal cancer screening test]
2010     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Efficacy, safety and economic assessment of the percutaneous aortic valve implantation]
2010     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Efficacy, safety and economic assessment of the percutaneous aortic valve implantation]
2013     Andalusian Health Technology Assessment Area (AETSA) [Efficacy, effectivity and efficiency of liquid cytology for cervical cancer screening and HPV infection diagnosis]
2017     Andalusian Health Technology Assessment Area (AETSA) [Efficacy, effectiveness and safety of physiotherapy in patients with multiple sclerosis. Rapid response]
2004     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Efficacy, effectiveness and safety of photodynamic therapy. Economical impact in the Community of Madrid]
2004     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Efficacy, effectiveness and safety of photodynamic therapy in age-related macular degeneration and pathologic myopia. Economic impact in the Community of Madrid]
2012     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Efficacy, effectiveness and safety of behavioural interventions in patients with autism spectrum disorders]
2010     Canary Health Service [Efficacy, effectiveness and efficiency of assertive community treatment for people with severe and persistent mental disorder and its relationship with the context of application]
2010     Andalusian Health Technology Assessment Area (AETSA) [Efficacy of oral/buccal insulin in the treatment of diabetes mellitus]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Efficacy of neglect interventions for Indigenous children, families and communities]
2008     Andalusian Health Technology Assessment Area (AETSA) [Efficacy of laparoscopy in hepatobiliary pathology]
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Efficacy of intraoperative radiation therapy]
2021     Basque Office for Health Technology Assessment (OSTEBA) [Efficacy of high flow oxygen therapy for the treatment of respiratory distress in children]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Efficacy of early intensive behavioral intervention in autism spectrum disorders]
2005     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Efficacy of colorectal cancer (CRC) screening in asymptomatic first degree relatives of patients with CRC or adenomas. Genetic tests]
2008     Andalusian Health Technology Assessment Area (AETSA) [Efficacy of biventricular pacemakers for heart failure]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [Efficacy of atomoxetine and methylphenidate in attention deficits hyperactivity disorder in adults: a rapid review]
2007     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Efficacy of 123i-ioflupane (DaTSCAN) on the diagnosis of parkinsonism syndromes. Systematic review and case registry]
2021     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Efficacy and safety of yoga on selected clinical conditions]
2013     Andalusian Health Technology Assessment Area (AETSA) [Efficacy and safety of ventricular assist devices]
2022     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Efficacy and safety of transanal irrigation in adults with bowel dysfunction]
2012     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Efficacy and safety of tocilizumab in treating rheumatoid arthritis]
2013     Andalusian Health Technology Assessment Area (AETSA) [Efficacy and safety of the Solitaire® flow restoration blood device]
2022     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Efficacy and safety of the pilates method in selected clinical conditions]
2012     Andalusian Health Technology Assessment Area (AETSA) [Efficacy and safety of the immunoregulatory drugs interferon beta and glatiramer in the treatment of relapsing remitting multiple sclerosis]